Showing 1471-1480 of 5771 results for "".
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Bausch + Lomb Announces Changes to its Leadership Teamhttps://modernod.com/news/bausch-lomb-solidifies-leadership-team/2481761/Bausch + Lomb announced changes to its executive leadership team, including the creation of two new roles. This development follows reshuffling announced in early June after chairman and CEO Brent Saunders rejoined B
- American Academy of Optometry Announces 2023 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2023-award-recipients/2481760/The American Academy of Optometry (AAO) announced the recipients of the 2023 AAO awards recognizing distinguished individuals who have made important contributions to advancing the profession of optometry. The awards will be presented during ceremonies at Academy 2023 New Orleans,
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRShttps://modernod.com/news/annexon-to-report-archer-phase-2-trial-results-in-geographic-atrophy-at-asrs/2481746/Annexon announced the company will present results from the ongoing ARCHER phase 2 trial in patients with geographic atrophy (GA) at the American Society of Retina Specialists (ASRS) 2023 annual meeting taking place July 28-August 1,
- IRIS and AEYE Health Announce Partnership to Provide AI Screening to Markethttps://modernod.com/news/iris-and-aeye-health-announce-partnership-to-provide-ai-screening-to-market/2481718/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with AEYE Health, an artificial intelligence company for retinal imaging and diagnostics. Under the agreement, IRIS will license AEYE Diagnostic Screening (AEYE-DS) from AEYE Health, which is an FDA-cleared AI technology that
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-chronic-thyroid-eye-disease-ted/2481716/Viridian Therapeutics announced positive preliminary data from its ongoing phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), in patients with chronic thyroid eye disease (TED). The company also announced an ame
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima
- Elios Vision Announces Collaboration with the International Glaucoma Surgical Registryhttps://modernod.com/news/elios-vision-announces-collaboration-with-the-international-glaucoma-surgical-registry/2481708/Elios Vision has announced its collaboration and support for the International Glaucoma Surgical Registry (IGSR), an open access tool which enables surgeons to upload and analyze their data and compare outcomes with other centers. The IGSR was established more than 5 years ago and currently
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s